DACLIZUMAB

Search structure
Trade Names:
Synonyms:
Status: Approved (1997)
Entry Type: Antibody
Molecule Category: UNKNOWN
ATC: L04AC01
UNII: CUJ2MVI71Y

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Interleukin-2 receptor inhibitor FDA DailyMed
Primary Target
Interleukin-2 receptor subunit α

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Multiple Sclerosis, Relapsing-Remitting 4 D020529 FDA
Graft vs Host Disease 3 D006086 ClinicalTrials
Multiple Sclerosis 3 D009103 ClinicalTrials
Diabetes Mellitus, Type 1 3 D003922 ClinicalTrials
Renal Insufficiency, Chronic 3 D051436 ClinicalTrials
Asthma 2 D001249 ClinicalTrials
Leukemia 2 D007938 ClinicalTrials
Uveitis 2 D014605 ClinicalTrials
Thrombocytopenia 2 D013921 ClinicalTrials
Anemia, Aplastic 2 D000741 ClinicalTrials
Red-Cell Aplasia, Pure 2 D012010 ClinicalTrials
Wet Macular Degeneration 2 D057135 ClinicalTrials
Myelodysplastic Syndromes 2 D009190 ClinicalTrials
Diabetes Mellitus 2 D003920 ClinicalTrials
Colitis, Ulcerative 2 D003093 ClinicalTrials
Red-Cell Aplasia, Pure 2 D012010 ClinicalTrials
Multiple Myeloma 2 D009101 ClinicalTrials
Granulomatosis with Polyangiitis 2 D014890 ClinicalTrials
Lymphoma 1 D008223 ClinicalTrials
Neoplasms 1 D009369 ClinicalTrials
Kidney Diseases 1 D007674 ClinicalTrials
Melanoma 1 D008545 ClinicalTrials
HIV Infections 1 D015658 ClinicalTrials
Psoriasis 1 D011565 ClinicalTrials
DiGeorge Syndrome 1 D004062 ClinicalTrials

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Nervous system disorders
19.81
General disorders and administration site conditions
14.57
Psychiatric disorders
8.39
Skin and subcutaneous tissue disorders
6.81
Gastrointestinal disorders
6.78
Musculoskeletal and connective tissue disorders
6.25
Infections and infestations
5.73
Respiratory, thoracic and mediastinal disorders
5.03
Injury, poisoning and procedural complications
4.33
Vascular disorders
3.53
Investigations
2.94
Immune system disorders
2.76
Renal and urinary disorders
2.27
Cardiac disorders
2.1

Cross References

Resources Reference
CAS NUMBER 152923-56-3
ChEMBL CHEMBL1201605
FDA SRS CUJ2MVI71Y
Guide to Pharmacology 6880
CONTENTS